Innovating Clinical Trials
Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.
Ted Trafford - https://traffordresearch.com/
With 29 years of experience in clinical research, Ted leads Feasibility, Business Development, and Site Relationship teams as Director of Business Development at Probity Medical Research, a clinical trial site administrative support company with a consortium of 70 sites across four countries. As a writer, advisor and speaker, Ted contributes to thought leadership and strategic initiatives in the clinical trials industry, leveraging his extensive experience and creative approach to drive meaningful discussion and progress for Sponsors, CROs, Sites and Technology Vendors.
Liam Eves - https://www.theendpointpodcast.com/
Liam's held executive roles in SMOs and CROs, and led all major functions of trial delivery. His journey into the field began unexpectedly after an injury ended his career as a professional footballer. Over the years Liam has optimized trial delivery methods / systems for effective enrollment and trial delivery. Currently, he focuses on building and advising companies in the clinical trial space.
Innovating Clinical Trials
ICT Ep13: Q2'24 The quarterly recap with Joel White (Part 2 of 3)
Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.
In this session we continue our discussion with Joel White from Marketcap Consulting about the financial performance of the clinical development space. We find out what Joel is bullish about and dive into the pre-clinical space.
Stay tuned for part 3.